Pharmaceutical

Otsuka and ShapeTX to develop gene therapies for eye diseases

Otsuka Pharmaceutical has entered a partnership with ShapeTX for the development of gene therapies to treat ocular diseases.

Sep 9, 2023 - 20:00
Otsuka and ShapeTX to develop gene therapies for eye diseases
Otsuka Pharmaceutical has entered a partnership with ShapeTX for the development of gene therapies to treat ocular diseases.
Read the original article

Tags:

Previous Article

Record number of respiratory syncytial virus (RSV) designations awarded in 2022

Next Article

NICE recommends Lilly’s tirzepatide to treat T2D

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Patient organisations need to tackle transparency

Patient organisations need to tackle transparency

Mar 14, 2024

Lilly bolsters IBD portfolio with $3.2bn Morphic acquisition

Lilly bolsters IBD portfolio with $3.2bn Morphic acquis...

Jul 10, 2024

RegenxBio touts positive data for rare disease drug RGX-121

RegenxBio touts positive data for rare disease drug RGX...

Sep 4, 2024